Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl-trna synthetases

Patent metadata

Field	Value
Publication number	US-2017190792-A1
Application number	US-201615365104-A
Country	US
Kind code	A1
Filing date	Nov 30, 2016
Priority date	Apr 29, 2010
Publication date	Jul 6, 2017
Grant date	—

Abstract

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

First claim

1 - 125 . (canceled)

126 . A therapeutic composition, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3, or Table(s) 4-6, and Table(s) 7-9, wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein.

127 . The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7.

128 . The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody.

129 . The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody.

130 . The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide.

131 . The therapeutic composition of claim 126 , wherein the composition is a sterile, freeze-dried powder.

132 . The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution.

133 . The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent.

134 . The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.

135 . The therapeutic composition of claim 126 , wherein the composition comprises a surfactant.

136 . The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis.

137 . A method of modulating a cellular activity of a cell, or protein, comprising contacting the cell or protein with a therapeutic composition of claim 126 .

138 . The method of claim 137 , wherein the cellular activity is selected from cell proliferation, cell differentiation, cell signaling, gene transcription, angiogenesis, cell binding, metabolism, cytokine production or activity, cytokine receptor activity, and inflammation.

139 . The method of claim 137 , wherein the cell type is selected from the group consisting of pre-adipocytes, bone marrow, neutrophils, blood cells, hepatocytes, astrocytes, mesenchymal stem cells, and skeletal muscle cells.

140 . The method of claim 137 , wherein the cell is in a subject.

141 . The method of claim 140 , comprising treating the subject, wherein the subject has a condition associated with a neoplastic disease, an immune system disease or condition, an inflammatory disorder, an infectious disease, a metabolic disease, neuronal/neurological disease, a muscular/cardiovascular disease, a disease associated with aberrant hematopoiesis, a disease associated with aberrant angiogenesis, or a disease associated with aberrant cell survival.

Assignees

• Atyr Pharma Inc
• Pangu Biopharma Ltd

Inventors

• Greene Leslie Ann
• Chiang Kyle P
• Hong Fei
• Vasserot Alain P
• Lo Wing-Sze
• Watkins Jeffry D
• Quinn Cheryl L
• Mendlein John D

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title